Digitally created image of brain in skull

ForeFront

RESEARCH CENTRE

Our laboratory research

At disease onset, focal pathology restricted to distinct brain areas is a feature of FTD and MND. However, the disease progresses and spreads by unknown mechanisms and the pattern of spread over time is poorly documented.

ForeFront will examine how progression occurs in the different clinical syndromes and proteinopathies using three main branches of laboratory-based research.

1. Human brain pathology – Prof Glenda Halliday and Prof Jillian Kril

Prof Halliday coordinated the first clinicopathological and survival studies published on frontotemporal disease and her laboratory developed the tool now used internationally to stage the disease. Prof Kril developed postmortem volumetric techniques, and is recognised for her quantitative studies on these and other neurodegenerative conditions. Their data are been used in all the pathological criteria for these diseases.

Key area of research for the first year:

Retrospective clinical analyses (Halliday and Hodges) – Postmortem cases will be stratified according to clinical syndromes and a range of defined candidate cognitive, linguistic, behavioural and radiological features assessed using multivariate statistics.

Retrospective pathological analyses (Kril) – We will apply a full range to immunohistological stains to the large clinically well-documented cohort of postmortem patients with particular clinical syndromes and multivariate statistics applied to identify features predictive of the underlying pathology.

2. Cellular and molecular studies – Assoc Prof Lars Ittner

Assoc Prof Ittner recently identified the mechanism of interaction between tau and Abeta, and has recently published cell TDP models using his new neuronal culture system.

Key area of research for the first year:
Molecular mechanisms of toxicity – A wide range of molecular mechanisms and pathways will be studied in primary cell culture to determine the contribution to cell death induced by different species (e.g. those identified above as contributing to progression) and mutant forms of tau, TDP43 and FUS. The protein-specific toxicity profiles will be compared to establish a complex network of shared and distinct modes of pathogenic pathways.

identification of vulnerability genes by forward genetics
3. Animal modelling – Prof Jürgen Götz

Prof Götz, who developed the first transgenic mouse model of frontotemporal disease, has continued to develop animal models and other tools to look at a variety of disease mechanisms.

Key area of research for the first year:

Identifying genes that confer protection – To identify protective genes, Affymetrix gene chips and differential gene expression will be used for transcriptional profiling of laser-captured dopamine neurons from K3 mice and non-transgenic controls, and validated with quantitative RT-PCR. We expect to identify several hundred candidate genes differentially expressed in dopamine neurons, a small subset of which will confer protection to tau-mediated neurodegeneration. To determine whether the ‘persisting’ genes confer ‘survival’, we will use in situ hybridisation and immunohistochemistry to analyse brain sections of a wide age range of K3 and non-transgenic control mice to determine which genes discriminate vulnerable from protected neurons.

How to get involved with research projects.

See what’s going on at NeuRA

FEEL THE BUZZ IN THE AIR? US TOO.

'I've got the best job for you dad. Your shaky arm will be perfect for it!'

Children… honest and insightful. Their innocence warms the heart. But what words do you use to explain to a child that daddy has an incurable brain disease? What words tell them that in time he may not be able to play football in the park, let alone feed himself? What words help them understand that in the later stages, dementia may also strike? Aged just 36, this was the reality that faced Steve Hartley. Parkinson's disease didn't care he was a fit, healthy, a young dad and devoted husband. It also didn't seem to care his family had no history of it. The key to defeating Parkinson's disease is early intervention, and thanks to a global research team, led by NeuRA, we're pleased to announce that early intervention may be possible. Your support, alongside national and international foundations Shake it Up Australia and the Michael J Fox Foundation, researchers have discovered that a special protein, found in people with a family history of the disease increases prior to Parkinson’s symptoms developing. This is an incredible step forward, because it means that drug therapies, aimed at blocking the increase in the protein, can be administered much earlier – even before symptoms strike. The next step is to understand when to give the drug therapies and which people will most benefit from it. But we need your help. A gift today will support vital research and in time help medical professionals around the world treat Parkinson’s disease sooner, with much better health outcomes. Thank you, in advance, for your support.  
APPEAL